Home / Stock ratings / GLP-1, Obesity and Biotech Stocks / ALNY
Stock rating · Pharmaceutical Preparations
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Rating & Analysis
As of September 28, 2026, MELANY rates Alnylam Pharmaceuticals, Inc. 62 out of 100 (Hold). Its highest factor score is earnings track record at 88, and its lowest is price momentum at 37.
MELANY ratingRated 2026-09-28ALNY · composite score
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in RNA interference (RNAi) therapeutics. RNAi is a naturally occurring cellular pathway for sequence-specific silencing and regulation of gene expression. Its commercial RNAi products, all developed and commercialized by Alnylam, include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1).
Rating as of 2026-09-28 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
Why ALNY scores 62/100
ALNY's 8 factor scores run from 37 to 88, and 5 of them sit above its composite of 62. Here is how ALNY breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- Forward P/E 19.6x, earnings growth accelerating
- PEG ratio 0.33 (< 1 = undervalued)
Margins, returns on capital, and balance-sheet strength.
- Gross margin 81%
- ROE 99%
Direction and relative strength of the recent share-price trend.
- Price +4.6% above 50-day MA
History of beating or missing estimates, and where estimates are heading.
- Avg EPS beat +45%
What Wall Street price targets and revisions are signalling.
- Analyst targets 45% upside
Near-term events that could move the stock.
- Earnings in 31 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How ALNY compares
As of October 14, 2026, Alnylam Pharmaceuticals, Inc. is tied for 13th of 20 in GLP-1, Obesity and Biotech Stocks, where the average score is 65.
Key risks for ALNY
- High debt-to-equity ratio 2.2x, rate-sensitive balance sheet
- Weak price momentum, trend not yet confirmed, may need more time to set up
Sector and theme context
Alnylam Pharmaceuticals, Inc. sits in the Healthcare sector theme, which MELANY currently rates 45/100 for strength. Theme strength feeds ALNY's momentum and catalyst factors above.
Tracking ALNY
Alnylam Pharmaceuticals, Inc. rates Hold right now, so MELANY is not flagging a fresh entry. Add ALNY to a watchlist in the app to follow its rating; an alert the moment it changes is part of Pro, free for 30 days.
How MELANY rates ALNY
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Alnylam Pharmaceuticals, Inc.'s 62/100 reflects mature factor weighting for its profile.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about ALNY
Is Alnylam Pharmaceuticals, Inc. (ALNY) a buy?
As of 2026-09-28, MELANY rated Alnylam Pharmaceuticals, Inc. Hold with a composite score of 62/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Alnylam Pharmaceuticals, Inc.'s MELANY score?
Alnylam Pharmaceuticals, Inc. (ALNY) has a MELANY composite score of 62/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the ALNY stock rating calculated?
MELANY scores ALNY from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Alnylam Pharmaceuticals, Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Alnylam Pharmaceuticals, Inc. (ALNY) Hold with a composite of 62/100 as of 2026-09-28. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the ALNY stock price forecast?
MELANY does not publish price targets or forecasts for ALNY. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 62/100 across eight factors for Alnylam Pharmaceuticals, Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is ALNY stock overvalued or undervalued?
MELANY's valuation factor currently reads 38/100 for Alnylam Pharmaceuticals, Inc., where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives ALNY's read.
What price should I buy ALNY at?
MELANY is not flagging a fresh entry for ALNY at its current Hold rating, so there is no entry zone to publish right now. Add ALNY to a watchlist in the app to follow it; an alert the moment the rating changes is part of Pro, free for 30 days.
What are the risks of buying ALNY stock?
The top risks MELANY currently flags for Alnylam Pharmaceuticals, Inc.: High debt-to-equity ratio 2.2x, rate-sensitive balance sheet; Weak price momentum, trend not yet confirmed, may need more time to set up. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Alnylam Pharmaceuticals, Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 71/100 for Alnylam Pharmaceuticals, Inc., and earnings track record, at 88/100. The 62/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will ALNY stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 37/100 for ALNY right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this ALNY rating?
The rating on this page is a snapshot of MELANY's read as of 2026-09-28. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores ALNY continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, ALNY included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.